Yusen Logistics Benelux Pharmaceutical Import Profile — Belgium (DGFT 2022–2026)

Name: Yusen Logistics Benelux Pharmaceutical Import Records from India — 3 Products, $7.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Yusen Logistics Benelux — Pharmaceutical Importer Profile (2026) | 3 Products, $7.8M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Yusen Logistics Benelux?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$240.0M	9,794	98.9%
Jubilant Generics Limited	$2.6M	206	1.1%

Yusen Logistics Benelux sources from 2 verified Indian suppliers across 5,038 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 98.9% of total imports, indicating a strategic single-source relationship.

What Formulations Does Yusen Logistics Benelux Import?

Formulation	Value	Ships
Esomeprazole magnesium gastro	$5.3M	157
Pantoprazol Gastro-Resistant tablets 40MG ( pantoprazol basics TAB 40MG ) Each tablet contains: pantoprazole sodium	$1.7M	77
Pantoprazol Gastro-Resistant tablets	$1.7M	42
Levetiracetam tablets 1000MG	$1.6M	46
Gabapentin capsules 300MG ( gabaran CAPS	$1.4M	31
Pantoprazole Gastro-Resistant tablets	$1.3M	44
Simvastatin tablets 20MG ( simva	$1.1M

What Products Does Yusen Logistics Benelux Import?

Top Products by Import Value

1Esomeprazole$4.3M 2Omeprazole$2.6M 3Magnesium$950.0K

Yusen Logistics Benelux Therapeutic Categories — 2 Specializations

Yusen Logistics Benelux imports across 2 therapeutic categories, with Gastrointestinal (87.9%), Vitamins & Supplements (12.1%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Gastrointestinal

2 products · 87.9% · $6.9M

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Esomeprazole	Gastrointestinal	$4.3M	86	0.9%	8
2	Omeprazole	Gastrointestinal	$2.6M	52	0.4%

Key Metrics

Total Import Value$7.8M

Products3

Shipments157

Categories2

CountryBelgium

#1 Rankings0

Indian Suppliers2

Formulations5,038

Top Categories

Gastrointestinal87.9%

Vitamins & Supplements12.1%

Last updated: March 28, 2026

Yusen Logistics Benelux — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Yusen Logistics Benelux is a subsidiary of Yusen Logistics, a global logistics provider with over 60 years of expertise in freight forwarding and transportation. Established in 2011, Yusen Logistics Benelux operates across Belgium, the Netherlands, and Luxembourg, offering comprehensive logistics solutions including warehousing, air and ocean freight, contract logistics, and origin cargo management services. The company serves various industries such as automotive, aerospace, retail, healthcare, technology, and food. (craft.co)

Headquartered in Moerdijk, Netherlands, Yusen Logistics Benelux has multiple facilities in Belgium, including locations in Beveren, Herentals, and Machelen. These facilities enable the company to provide efficient logistics services throughout the Benelux region. (craft.co)

2Distribution Network

Yusen Logistics Benelux operates a robust distribution network with multiple facilities across Belgium, the Netherlands, and Luxembourg. In Belgium, the company has warehouses in Beveren, Herentals, and Machelen, strategically located to serve various industries, including pharmaceuticals. The company's logistics capabilities encompass air and ocean freight, contract logistics, and origin cargo management services, ensuring efficient supply chain operations. (craft.co)

Supplier Relationship Intelligence — Yusen Logistics Benelux

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Yusen Logistics Benelux's sourcing strategy exhibits a high degree of concentration, with 98.9% of its pharmaceutical imports from India supplied by SUN PHARMACEUTICAL INDUSTRIES LIMITED. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and regulatory changes affecting the supplier. The company's reliance on a single supplier suggests a strategic choice to leverage established relationships and ensure consistent product quality. However, the limited supplier base may impact the stability of the supply chain, especially in the event of unforeseen disruptions.

2Supply Chain Resilience

The resilience of Yusen Logistics Benelux's Indian supply chain is contingent upon the stability and reliability of SUN PHARMACEUTICAL INDUSTRIES LIMITED. The company's exclusive sourcing from this supplier indicates a deep integration and reliance on their operations. The absence of backup suppliers and limited formulation diversity may expose the supply chain to risks associated with production delays, quality issues, or regulatory challenges affecting the primary supplier. Additionally, the company's shipping routes and regulatory compliance are closely tied to SUN PHARMACEUTICAL INDUSTRIES LIMITED's operations, further emphasizing the need for a robust and resilient supply chain strategy.

3Strategic Implications

Yusen Logistics Benelux's concentrated sourcing strategy positions the company to benefit from strong supplier relationships and potential cost efficiencies. However, the heavy reliance on a single supplier may limit flexibility and responsiveness to market changes. For Indian exporters, this presents an opportunity to diversify their customer base by offering alternative products or formulations that align with Yusen Logistics Benelux's needs, potentially reducing the company's dependency on a single supplier and enhancing supply chain resilience.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Belgium — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Belgium

1Regulatory Authority & Framework

In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) is the primary regulatory authority overseeing pharmaceutical imports. The Royal Decree of 4 September 2022, amending the Royal Decree of 19 April 2001, governs the parallel import of medicines for human use. This legislation outlines the conditions and procedures for obtaining a parallel import license, including requirements for marketing authorization in the exporting European Economic Area (EEA) state.

2Import Licensing & GMP

Import licensing in Belgium requires compliance with FAMHP regulations, including obtaining a parallel import license for medicines. Good Manufacturing Practice (GMP) certificates recognized by the European Union (EU), World Health Organization (WHO), or Pharmaceutical Inspection Co-operation Scheme (PIC/S) are essential for ensuring product quality and safety. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of pharmaceutical products within Belgium.

3Quality & Labeling

Pharmaceutical products imported into Belgium must undergo batch testing to verify quality and safety. Stability requirements ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in Dutch, French, and German, providing clear information on usage, dosage, and storage. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

4Recent Regulatory Changes

Between 2024 and 2026, Belgium has implemented regulatory changes to facilitate the parallel import of pharmaceuticals. Notably, the Royal Decree of 4 September 2022, effective from 16 September 2022, removed the requirement that the imported medicinal product must have the same therapeutic indications as the Belgian reference product. This amendment simplifies the process for obtaining a parallel import license, potentially increasing the availability of imported medicines in the Belgian market.

TransData Nexus Research · Belgium regulatory databasesMar 2026

Seller's Guide — How to Become a Supplier to Yusen Logistics Benelux

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Yusen Logistics Benelux, particularly by offering alternative products or formulations that align with the company's import strategy. Diversifying the supplier base can enhance supply chain resilience and reduce dependency on a single source. Identifying gaps in Yusen Logistics Benelux's current sourcing, such as unmet therapeutic needs or emerging market trends, can provide avenues for new suppliers to introduce innovative products that meet the evolving demands of the Belgian pharmaceutical market.

2Requirements & Qualifications

Indian exporters aiming to supply Yusen Logistics Benelux and the Belgian market must ensure compliance with EU GMP standards and obtain the necessary certifications recognized by FAMHP. Products must meet the quality and safety standards stipulated by Belgian regulations, including batch testing and stability requirements. Additionally, labeling must be in the official languages of Belgium—Dutch, French, and German—and adhere to serialization mandates to facilitate traceability and prevent counterfeit products.

3How to Approach

Indian exporters should initiate engagement with Yusen Logistics Benelux by demonstrating compliance with EU GMP standards and presenting products that meet the quality and regulatory requirements of the Belgian market. Participating in tenders and responding to requests for proposals can provide opportunities to showcase product offerings. Developing a clear regulatory filing strategy, including obtaining the necessary certifications and approvals, is essential. Establishing a timeline that accounts for regulatory processes, quality assurance procedures, and logistical considerations will facilitate a smooth entry into the Belgian pharmaceutical market.

TransData Nexus Research · Industry procurement practicesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Yusen Logistics Benelux identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Yusen Logistics Benelux's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 157 individual customs records matching Yusen Logistics Benelux.
5.Supplier Verification: Yusen Logistics Benelux sources from 2 verified Indian suppliers across 5,038 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

3 Products Tracked

2 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Yusen Logistics Benelux

Yusen Logistics Benelux — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Yusen Logistics Benelux?

What Formulations Does Yusen Logistics Benelux Import?

What Products Does Yusen Logistics Benelux Import?

Top Products by Import Value

Yusen Logistics Benelux Therapeutic Categories — 2 Specializations

Import Portfolio — Top 3 by Import Value

Key Metrics

Top Categories

Yusen Logistics Benelux — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Yusen Logistics Benelux

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Belgium — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Yusen Logistics Benelux — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Yusen Logistics Benelux

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Yusen Logistics Benelux

What products does Yusen Logistics Benelux import from India?

Who supplies pharmaceuticals to Yusen Logistics Benelux from India?

What is Yusen Logistics Benelux's total pharmaceutical import value?

What therapeutic categories does Yusen Logistics Benelux focus on?

Get Full Yusen Logistics Benelux Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology